New medicines
Seractil
Composition: Dexibuprofen.
Presentation: Film-coated tablets.
Class: Anti-inflammatory and antirheumatic product.
Indications: Symptomatic treatment for the relief of pain and inflammation
associated with osteoarthritis or other forms of mild to moderate pain
such as muscular-skeletal pain or dental pain. Acute symptomatic treatment
of pain during menstrual bleeding.
Dosage: 600 to 900mg daily, divided in up to three single doses. Maximum
single dose 400mg.
Precautions: Care is recommended in conditions that predispose patients
to the gastrointestinal adverse effects of NSAIDs, and in elderly patients.
In the rare instances where gastrointestinal bleeding or ulceration occurs,
dexibuprofen should be discontinued immediately. In the treatment of
patients with heart failure, hypertension, renal or hepatic disease,
especially during concomitant diuretic treatment, the risk of fluid retention
and a deterioration in renal function must be taken into account. See
SPC.
Contraindications: Include patients in whom substances with a similar
action precipitate attacks of asthma, bronchospasm, acute rhinitis or
cause nasal polyps, urticaria or angioneurotic oedema. Patients with
gastrointestinal ulcers, bleeding disorders, Crohn’s disease, active
ulcerative colitis, heart failure, severe renal dysfunction or severely
impaired hepatic function. See SPC.
Side effects: Most common are gastrointestinal. See SPC.
Legal category: POM.
Net price: 300mg 60 £9.47, 400mg 60 £9.97.
Contact details: Genus Pharmaceuticals, Benham Valence, Newbury, Berkshire
RG20 8LU. Telephone 01635 568 400.
Back to Top
|
The
Pharmaceutical Journal